Mingzhao Xing

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3602530/publications.pdf

Version: 2024-02-01

134 papers	15,810 citations	19657 61 h-index	16650 123 g-index
136 all docs	136 docs citations	136 times ranked	10654 citing authors

#	Article	IF	Citations
1	Response to Letter to the Editor from Boucai and Tuttle: â€œBRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancerâ€• Journal of Clinical Endocrinology and Metabolism, 2022, , .	3.6	0
2	Therapeutic targeting of FOS in mutant <i>TERT</i> cancers through removing TERT suppression of apoptosis via regulating <i>survivin</i> and <i>TRAIL-R2</i>. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	13
3	UPF1 reduces C9orf72 HRE-induced neurotoxicity in the absence of nonsense-mediated decay dysfunction. Cell Reports, 2021, 34, 108925.	6.4	14
4	Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients. BMC Cancer, 2021, 21, 543.	2.6	10
5	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	3.6	36
6	The Genetic Duet of <i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. Journal of Nuclear Medicine, 2020, 61, 177-182.	5.0	78
7	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	2.8	41
8	<i>TERT</i> promoter mutation determines apoptotic and therapeutic responses of <i>BRAF</i> -mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15846-15851.	7.1	31
9	CRISPR-Cas9 Screens Identify the RNA Helicase DDX3X as a Repressor of C9ORF72 (GGGGCC)n Repeat-Associated Non-AUG Translation. Neuron, 2019, 104, 885-898.e8.	8.1	107
10	Decreased breast cancer-specific mortality risk in patients with a history of thyroid cancer. PLoS ONE, 2019, 14, e0221093.	2.5	11
11	Stage II Differentiated Thyroid Cancer Is a High-Risk Disease in Patients <45/55 Years Old. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4941-4948.	3.6	3
12	Genetic-guided Risk Assessment and Management of Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 109-124.	3.2	44
13	Entering an Era of Precision Management of Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, xvii-xviii.	3.2	2
14	Identification and characterization of two novel oncogenic mTOR mutations. Oncogene, 2019, 38, 5211-5226.	5.9	24
15	Inositol hexakisphosphate kinase 3 promotes focal adhesion turnover via interactions with dynein intermediate chain 2. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3278-3287.	7.1	14
16	Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nature Communications, 2018, 9, 579.	12.8	140
17	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	6.3	60
18	C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2Î± phosphorylation. Nature Communications, 2018, 9, 51.	12.8	166

#	Article	IF	Citations
19	Reply to M. Melo et al. Journal of Clinical Oncology, 2018, 36, 1457-1458.	1.6	2
20	Patient Ageâ€"Associated Mortality Risk Is Differentiated by <i>BRAF</i> V600E Status in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 438-445.	1.6	102
21	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	1.6	58
22	Multiple aspects of male germ cell development and interactions with Sertoli cells require inositol hexakisphosphate kinase-1. Scientific Reports, 2018, 8, 7039.	3.3	19
23	Neuronal migration is mediated by inositol hexakisphosphate kinase 1 via Î±-actinin and focal adhesion kinase. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2036-2041.	7.1	50
24	When Somatic Mutations Are Associated With a Higher Aggressive Behaviorâ€"A Story of Announced Evidenceâ€"Reply. JAMA Oncology, 2017, 3, 1428.	7.1	0
25	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	3.6	80
26	A six-genotype genetic prognostic model for papillary thyroid cancer. Endocrine-Related Cancer, 2017, 24, 41-52.	3.1	63
27	Mortality Risk Stratification by Combining <i>BRAF </i>V600E and <i>TERT</i> Promoter Mutations in Papillary Thyroid Cancer. JAMA Oncology, 2017, 3, 202.	7.1	217
28	Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. Oncotarget, 2017, 8, 900-914.	1.8	12
29	<i>BRAF</i>and<i>TERT</i>promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget, 2016, 7, 18346-18355.	1.8	109
30	Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a â€œTibetan Mastiff Dogâ€•From Puppies. Journal of Cellular Biochemistry, 2016, 117, 1491-1496.	2.6	10
31	Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer. BMC Medicine, 2016, 14, 12.	5.5	78
32	TERT promoter mutations in thyroid cancer. Endocrine-Related Cancer, 2016, 23, R143-R155.	3.1	301
33	Recent incidences and differential trends of thyroid cancer in the USA. Endocrine-Related Cancer, 2016, 23, 313-322.	3.1	164
34	Diagnostic and Prognostic Molecular Markers in Thyroid Cancer. , 2016, , 281-292.		1
35	Response. Journal of the National Cancer Institute, 2016, 108, djw124.	6.3	0
36	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	3.6	179

#	Article	IF	Citations
37	<i>HABP2</i>G534E Mutation in Familial Nonmedullary Thyroid Cancer. Journal of the National Cancer Institute, 2016, 108, djv415.	6.3	33
38	Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 962-971.	3.6	29
39	Uncommon <i>TERT</i> Promoter Mutations in Pediatric Thyroid Cancer. Thyroid, 2016, 26, 235-241.	4.5	31
40	Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data. PLoS ONE, 2016, 11, e0159235.	2.5	12
41	Characterization of the novel tumor-suppressor gene <i>CCDC67</i> in papillary thyroid carcinoma. Oncotarget, 2016, 7, 5830-5841.	1.8	30
42	The sonic hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met. Oncotarget, 2016, 7, 10472-10485.	1.8	31
43	<i>BRAF</i> Mutation and Thyroid Cancer Recurrence. Journal of Clinical Oncology, 2015, 33, 2482-2483.	1.6	18
44	Association of<i>TERT</i>Promoter Mutation 1,295,228 C>T With<i>BRAF</i>V600E Mutation, Older Patient Age, and Distant Metastasis in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E632-E637.	3.6	76
45	BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocrine-Related Cancer, 2015, 22, 159-168.	3.1	102
46	Acoustic Radiation Force Impulse Elastography in the Diagnosis of Thyroid Nodules: Useful or Not Useful?. Ultrasound in Medicine and Biology, 2015, 41, 2581-2593.	1.5	17
47	Simultaneous suppression of the MAP kinase and NF-Î°B pathways provides a robust therapeutic potential for thyroid cancer. Cancer Letters, 2015, 368, 46-53.	7.2	25
48	Reply to M. Melo et al. Journal of Clinical Oncology, 2015, 33, 668-669.	1.6	0
49	Reply to C. Bal et al. Journal of Clinical Oncology, 2015, 33, 2483-2484.	1.6	1
50	Quantitative Shear Wave Velocity Measurement on Acoustic Radiation Force Impulse Elastography for Differential Diagnosis between Benign and Malignant Thyroid Nodules: AÂMeta-analysis. Ultrasound in Medicine and Biology, 2015, 41, 3035-3043.	1.5	47
51	Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid, 2015, 25, 1097-1105.	4.5	20
52	TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocrine-Related Cancer, 2015, 22, 901-908.	3.1	42
53	Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology, 2015, 33, 42-50.	1.6	448
54	<i>REC8</i>is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer. Oncotarget, 2015, 6, 39211-39224.	1.8	26

#	Article	IF	Citations
55	RASAL1 in Thyroid Cancer: Promise From a New Friend. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3619-3621.	3.6	4
56	Activities of multiple cancer-related pathways are associated with<i>BRAF</i>mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Cell Cycle, 2014, 13, 208-219.	2.6	31
57	<i>TERT</i>Promoter Mutations and Their Association with<i>BRAF</i>V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1130-E1136.	3.6	262
58	Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocrine-Related Cancer, 2014, 21, 161-173.	3.1	83
59	Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocrine-Related Cancer, 2014, 21, 825-830.	3.1	77
60	<i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence. Journal of Clinical Oncology, 2014, 32, 2718-2726.	1.6	595
61	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	7.4	775
62	<i>BRAF</i>V600E Mutation and Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 310, 535.	7.4	32
63	Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews Cancer, 2013, 13, 184-199.	28.4	1,125
64	Highly prevalent<i>TERT</i>promoter mutations in bladder cancer and glioblastoma. Cell Cycle, 2013, 12, 1637-1638.	2.6	123
65	Progress in molecular-based management of differentiated thyroid cancer. Lancet, The, 2013, 381, 1058-1069.	13.7	496
66	Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocrine-Related Cancer, 2013, 20, 13-22.	3.1	41
67	<i>BRAF</i>V600E Mutation and Papillary Thyroid Cancerâ€"In Reply. JAMA - Journal of the American Medical Association, 2013, 310, 534.	7.4	5
68	DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. Endocrine-Related Cancer, 2013, 20, 507-514.	3.1	29
69	Identification of RASAL1 as a Major Tumor Suppressor Gene in Thyroid Cancer. Journal of the National Cancer Institute, 2013, 105, 1617-1627.	6.3	81
70	Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer, 2013, 20, 603-610.	3.1	500
71	Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*. Journal of Biological Chemistry, 2013, 288, 6511-6521.	3.4	40
72	Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer. Oncology Letters, 2013, 6, 437-441.	1.8	11

#	Article	IF	Citations
73	<i>BRAF</i>^{V600E}Mutation and Papillary Thyroid Cancer: Chicken or Egg?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2295-2298.	3.6	24
74	BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment. Medicine (United States), 2012, 91, 274-286.	1.0	264
75	The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAF^{V600E}Inhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E173-E182.	3.6	58
76	The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle, 2012, 11, 286-295.	2.6	84
77	Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma. Biochemical and Biophysical Research Communications, 2012, 425, 45-50.	2.1	10
78	Single Nucleotide Polymorphism rs17849071 G/T in the PIK3CA Gene Is Inversely Associated with Follicular Thyroid Cancer and PIK3CA Amplification. PLoS ONE, 2012, 7, e49192.	2.5	17
79	Oxidative stress: a new risk factor for thyroid cancer. Endocrine-Related Cancer, 2012, 19, C7-C11.	3.1	79
80	Induction of Sodium/Iodide Symporter (NIS) Expression and Radioiodine Uptake in Non-Thyroid Cancer Cells. PLoS ONE, 2012, 7, e31729.	2.5	28
81	The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E577-E585.	3.6	93
82	The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochemical and Biophysical Research Communications, 2011, 404, 958-962.	2.1	47
83	Association of Cigarette Smoking with Aberrant Methylation of the Tumor Suppressor Gene RAR?2 in Papillary Thyroid Cancer. Frontiers in Endocrinology, 2011, 2, 99.	3.5	12
84	Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocrine-Related Cancer, 2011, 18, 687-697.	3.1	70
85	Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers. Endocrine Pathology, 2011, 22, 97-102.	9.0	33
86	Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the <i>ALK</i> Gene. Cancer Research, 2011, 71, 4403-4411.	0.9	190
87	Genetic and Epigenetic Alterations in the MAP Kinase and PI3K/Akt Pathways in Thyroid Cancer. , 2011, , 27-38.		0
88	<i>BRAF</i> mutationâ€selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and geneticâ€potentiated synergism with the mTOR inhibitor temsirolimus. International Journal of Cancer, 2010, 127, 2965-2973.	5.1	52
89	IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer. Clinical Cancer Research, 2010, 16, 6009-6018.	7.0	54
90	Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer. Thyroid, 2010, 20, 697-706.	4.5	258

#	Article	IF	Citations
91	Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 820-828.	3.6	104
92	Prognostic utility of BRAF mutation in papillary thyroid cancer. Molecular and Cellular Endocrinology, 2010, 321, 86-93.	3.2	188
93	Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochemical and Biophysical Research Communications, 2010, 393, 555-559.	2.1	122
94	Induction of Heparanase-1 Expression by Mutant B-Raf Kinase: Role of GA Binding Protein in Heparanase-1 Promoter Activation. Neoplasia, 2010, 12, 946-956.	5.3	23
95	Genetic-Targeted Therapy of Thyroid Cancer: A Real Promise. Thyroid, 2009, 19, 805-809.	4.5	13
96	Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin. Cancer Research, 2009, 69, 7311-7319.	0.9	84
97	Association of High Iodine Intake with the T1799A BRAF Mutation in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1612-1617.	3.6	189
98	MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle, 2009, 8, 2122-2124.	2.6	73
99	Identifying Genetic Alterations in Poorly Differentiated Thyroid Cancer: A Rewarding Pursuit. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4661-4664.	3.6	9
100	BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management. Annals of Surgical Oncology, 2009, 16, 801-803.	1.5	47
101	<i>BRAF</i> Mutation Testing of Thyroid Fine-Needle Aspiration Biopsy Specimens for Preoperative Risk Stratification in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2009, 27, 2977-2982.	1.6	256
102	[Comments on the Ito et al. article (Endocr J. 2008 Oct 8. Epub ahead of print)] The Lack of Clinicopathological Correlation of BRAF Mutation in Papillary Thyroid Cancer Needs to Be Interpreted with Caution. Endocrine Journal, 2009, 56, 305-306.	1.6	5
103	Induction of Thyroid Gene Expression and Radioiodine Uptake in Melanoma Cells: Novel Therapeutic Implications. PLoS ONE, 2009, 4, e6200.	2.5	17
104	Hypermethylation of the DNA mismatch repair gene <i>hMLH1</i> and Its association with lymph node metastasis and T1799A <i>BRAF</i> mutation in patients with papillary thyroid cancer. Cancer, 2008, 113, 247-255.	4.1	65
105	Association of <i>PTEN</i> gene methylation with genetic alterations in the phosphatidylinositol 3â€kinase/AKT signaling pathway in thyroid tumors. Cancer, 2008, 113, 2440-2447.	4.1	138
106	Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical Implications. Otolaryngologic Clinics of North America, 2008, 41, 1135-1146.	1.1	70
107	Potent Inhibition of Thyroid Cancer Cells by the MEK Inhibitor PD0325901 and Its Potentiation by Suppression of the PI3K and NF-ÎºB Pathways. Thyroid, 2008, 18, 853-864.	4.5	67
108	Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocrine-Related Cancer, 2008, 15, 183-190.	3.1	41

#	Article	IF	Citations
109	Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3106-3116.	3.6	349
110	BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2264-2271.	3.6	110
111	Functional Characterization of the T1799-1801del and G1799-1816ins BRAF Mutations in Papillary Thyroid Cancer. Cell Cycle, 2007, 6, 377-379.	2.6	86
112	Inhibitory Effects of the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 on the Proliferation and Tumor Growth of Thyroid Cancer Cells with<i>BRAF</i>or<i>RAS</i>Mutations. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4686-4695.	3.6	65
113	High Prevalence and Mutual Exclusivity of Genetic Alterations in the Phosphatidylinositol-3-Kinase/Akt Pathway in Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2387-2390.	3.6	154
114	Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4712-4718.	3.6	95
115	Lack of Mutations in the Thyroid Hormone Receptor (TR) Î± and Î² Genes but Frequent Hypermethylation of the TRÎ² Gene in Differentiated Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4766-4770.	3.6	40
116	Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant. Clinical Cancer Research, 2007, 13, 1341-1349.	7.0	166
117	Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer. Clinical Cancer Research, 2007, 13, 1161-1170.	7.0	362
118	BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications. Endocrine Reviews, 2007, 28, 742-762.	20.1	857
119	Gene Methylation in Thyroid Tumorigenesis. Endocrinology, 2007, 148, 948-953.	2.8	168
120	BRAF mutation in thyroid carcinogenesis and its clinical implications. Current Opinion in Endocrinology, Diabetes and Obesity, 2006, 13, 455-459.	0.6	2
121	Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. International Journal of Cancer, 2006, 119, 2322-2329.	5.1	162
122	Detection of Serum Deoxyribonucleic Acid Methylation Markers: A Novel Diagnostic Tool for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 98-104.	3.6	59
123	Absence of Germline Mutations in Genes within the MAP Kinase Pathway in Familial Nonmedullary Thyroid Cancer. Cell Cycle, 2006, 5, 2036-2039.	2.6	18
124	The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Clinical Endocrinology, 2005, 63, 263-266.	2.4	41
125	High Prevalence and Possible de Novo Formation of BRAF Mutation in Metastasized Papillary Thyroid Cancer in Lymph Nodes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5265-5269.	3.6	114
126	Letter re: Uncommon Mutation but Common Amplifications of thePIK3CAGene in Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5509-5509.	3.6	8

#	Article	IF	Citations
127	Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4688-4693.	3.6	189
128	BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6373-6379.	3.6	893
129	Early Occurrence of <i>RASSF1A</i> Hypermethylation and Its Mutual Exclusion with <i>BRAF</i> Mutation in Thyroid Tumorigenesis. Cancer Research, 2004, 64, 1664-1668.	0.9	142
130	Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens: A New Diagnostic Tool for Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2867-2872.	3.6	239
131	BRAF Mutation in Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 2003, 95, 625-627.	6.3	849
132	Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis. Cancer Research, 2003, 63, 2312-5.	0.9	54
133	Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Research, 2003, 63, 2316-21.	0.9	107
134	Extracellular ATP and cAMP as Paracrine and Interorgan Regulators of Renal Function P2Y Receptors of MDCK Cells: Epithelial Cell Regulation by Extracellular Nucleotides. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 351-354.	1.9	59